Clinical trial
Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of…
NCT00498654 · Avant Immunotherapeutics, Industry · Completed
Key facts
| NCT number | NCT00498654 |
|---|---|
| Title | Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects |
| Official title | A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of a Single Oral Dose Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects |
| Lead sponsor | Avant Immunotherapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Typhoid Fever |
| Intervention type | Biological |
| Interventions | Ty800 (Salmonella typhi) Oral Vaccine |
| Enrollment | 180 |
| Start date | Jul 1, 2007 |
| Primary completion | Oct 1, 2007 |
| Completion | Jun 1, 2008 |
| First posted | Jul 10, 2007 |
| Last update posted | Jul 2, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: